CN1688285A - Dna诱变损伤的修复 - Google Patents

Dna诱变损伤的修复 Download PDF

Info

Publication number
CN1688285A
CN1688285A CNA038240114A CN03824011A CN1688285A CN 1688285 A CN1688285 A CN 1688285A CN A038240114 A CNA038240114 A CN A038240114A CN 03824011 A CN03824011 A CN 03824011A CN 1688285 A CN1688285 A CN 1688285A
Authority
CN
China
Prior art keywords
alkyl
aryl
hydrogen
skin
aralkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038240114A
Other languages
English (en)
Chinese (zh)
Inventor
G·E·凯利
A·哈斯班德
C·沃尔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kazia Research Pty Ltd
Original Assignee
Novogen Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen Research Pty Ltd filed Critical Novogen Research Pty Ltd
Publication of CN1688285A publication Critical patent/CN1688285A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
CNA038240114A 2002-09-06 2003-09-05 Dna诱变损伤的修复 Pending CN1688285A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002951271A AU2002951271A0 (en) 2002-09-06 2002-09-06 Repair of dna mutagenic damage
AU2002951271 2002-09-06

Publications (1)

Publication Number Publication Date
CN1688285A true CN1688285A (zh) 2005-10-26

Family

ID=27671591

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038240114A Pending CN1688285A (zh) 2002-09-06 2003-09-05 Dna诱变损伤的修复

Country Status (11)

Country Link
US (1) US20060153781A1 (https=)
EP (1) EP1534232A4 (https=)
JP (1) JP2006501252A (https=)
CN (1) CN1688285A (https=)
AU (1) AU2002951271A0 (https=)
CA (1) CA2497823A1 (https=)
CZ (1) CZ2005136A3 (https=)
MX (1) MXPA05002519A (https=)
NO (1) NO20051605D0 (https=)
TR (1) TR200500749T2 (https=)
WO (1) WO2004022023A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114831981A (zh) * 2021-02-02 2022-08-02 上海交通大学 一种ERβ选择性激动剂在抗肿瘤中的应用
CN117599041A (zh) * 2024-01-22 2024-02-27 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104643057A (zh) 2002-07-24 2015-05-27 儿童医院医疗中心 含有对映体牛尿酚的组合物和产物及其用途
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
WO2004039327A2 (en) 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
EP1542654A4 (en) * 2002-09-23 2008-12-17 Novogen Res Pty Ltd TREATMENT OF PHOTOTATIOOD AND ACTINIC DETERIORATION OF THE SKIN
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
CA2738510A1 (en) * 2008-07-30 2010-02-04 Novogen Research Pty Ltd 6-substituted isoflavonoid compounds and uses thereof
HRP20240793T1 (hr) 2018-04-18 2024-09-13 Constellation Pharmaceuticals, Inc. Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
LT4003532T (lt) 2019-07-24 2024-11-11 Constellation Pharmaceuticals, Inc. 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
AUPP112497A0 (en) * 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
AUPP868599A0 (en) * 1999-02-15 1999-03-11 Novogen Research Pty Ltd Production of isoflavone derivatives
DE10121375B4 (de) * 2001-05-02 2014-01-16 Beiersdorf Ag Verwendung von Isoflavonoiden in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
DE10122342A1 (de) * 2001-05-09 2002-11-14 Beiersdorf Ag Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114831981A (zh) * 2021-02-02 2022-08-02 上海交通大学 一种ERβ选择性激动剂在抗肿瘤中的应用
CN117599041A (zh) * 2024-01-22 2024-02-27 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途

Also Published As

Publication number Publication date
NO20051605L (no) 2005-03-30
NO20051605D0 (no) 2005-03-30
TR200500749T2 (tr) 2005-10-21
EP1534232A4 (en) 2008-12-24
CZ2005136A3 (cs) 2006-04-12
AU2002951271A0 (en) 2002-09-19
EP1534232A1 (en) 2005-06-01
JP2006501252A (ja) 2006-01-12
CA2497823A1 (en) 2004-03-18
WO2004022023A1 (en) 2004-03-18
US20060153781A1 (en) 2006-07-13
MXPA05002519A (es) 2005-06-17

Similar Documents

Publication Publication Date Title
CN1056608C (zh) 含咪唑基的假二肽产物及其应用
CN1688285A (zh) Dna诱变损伤的修复
CN1038585C (zh) ２，４－和２，５－取代吡啶－ｎ－氧化物的制备方法
CN1136832C (zh) 皱纹改善剂
CN1638725A (zh) 包含类视黄醇的稳定的个人护理组合物
CN1688287A (zh) 包含衍生自间苯二酚衍生物的香豆素的亮肤剂
CN1893919A (zh) 局部施用的杀体内寄生虫组合物
CN1394594A (zh) 氨基酸衍生物基组合物及用途和溶解低溶解度物质的方法
CN1144475A (zh) 阿尔发羟基酸、阿尔发酮酸和相关化合物的多氨盐
CN1241132A (zh) 皮肤外用剂
CN1681500A (zh) 皮肤病的局部治疗
CN1993106A (zh) 新的皮肤病学的组合物
HK1081853A (en) Repair of dna mutagenic damage
US20060153782A1 (en) Skin photoageing and actinic damage treatment
CN1173692C (zh) 化妆品组合物和降低皮肤老化过程的方法
CN1055389C (zh) 抗皮肤生斑和/或衰老的组合物及其用途
CN1553797A (zh) 羧酸门控的硝基氧(cgn)化合物和组合物以及使用其的方法
CN114341100A (zh) 用于亮肤的新型化合物
CN1266676A (zh) 美容用防晒组合物
CN1283451A (zh) 含有生育酚的局部组合物
CN1106658A (zh) 表皮用制剂和其制备方法
CN1688286A (zh) 皮肤光老化和光化性损害的治疗方法
AU2003257264A1 (en) Repair of dna mutagenic damage
HK1029943B (en) A cosmetic composition and a method for reducing the ageing processes of skin
CN1646121A (zh) 用于调控光毒性的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1081853

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20051026

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1081853

Country of ref document: HK